ATE540051T1 - Age-inhibitoren - Google Patents

Age-inhibitoren

Info

Publication number
ATE540051T1
ATE540051T1 AT06725441T AT06725441T ATE540051T1 AT E540051 T1 ATE540051 T1 AT E540051T1 AT 06725441 T AT06725441 T AT 06725441T AT 06725441 T AT06725441 T AT 06725441T AT E540051 T1 ATE540051 T1 AT E540051T1
Authority
AT
Austria
Prior art keywords
halogen atoms
groups
group
amino acid
optionally substituted
Prior art date
Application number
AT06725441T
Other languages
English (en)
Inventor
Nobumichi Sasaki
Garcia Alvarez Maria Achab
Qian Wang-Zhu
Lioudmila Ermolenko
Joanna Bakala
Gisele Franck
Nhiri Naima Bakrim
Pierre Potier
Original Assignee
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of ATE540051T1 publication Critical patent/ATE540051T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06086Dipeptides with the first amino acid being basic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0815Tripeptides with the first amino acid being basic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
AT06725441T 2005-03-31 2006-03-30 Age-inhibitoren ATE540051T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0503176A FR2883873B1 (fr) 2005-03-31 2005-03-31 Inhibiteurs d'age
PCT/EP2006/061191 WO2006103274A1 (fr) 2005-03-31 2006-03-30 Inhibiteurs d'age

Publications (1)

Publication Number Publication Date
ATE540051T1 true ATE540051T1 (de) 2012-01-15

Family

ID=34955359

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06725441T ATE540051T1 (de) 2005-03-31 2006-03-30 Age-inhibitoren

Country Status (16)

Country Link
US (2) US20080249030A1 (de)
EP (1) EP1863832B1 (de)
JP (1) JP4695186B2 (de)
KR (2) KR101536839B1 (de)
CN (1) CN101268093B (de)
AT (1) ATE540051T1 (de)
AU (1) AU2006228163A1 (de)
BR (1) BRPI0609783A8 (de)
CA (1) CA2603386C (de)
EA (1) EA200702104A1 (de)
FR (1) FR2883873B1 (de)
GE (1) GEP20104882B (de)
MA (1) MA29416B1 (de)
MX (1) MX2007012238A (de)
WO (1) WO2006103274A1 (de)
ZA (1) ZA200708835B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101646416B (zh) * 2007-03-20 2011-08-17 株式会社资生堂 皮肤外用组合物
WO2010136182A1 (en) * 2009-05-29 2010-12-02 Ruprecht-Karls-Universität Heidelberg Methylglyoxal-scavenging compounds and their use for the prevention and treatment of pain and/or hyperalgesia
JP5787339B2 (ja) * 2009-12-28 2015-09-30 学校法人福岡大学 糖尿病前症の検査方法
FR2981073B1 (fr) * 2011-10-07 2013-12-27 Pharmamens Composes piegeurs d'alpha-oxoaldehydes et d'aldehydes alpha, beta-insatures, compositions les contenant et leurs utilisations dans des traitements de maladies liees a l'accumulation des age et ale.
US20160024233A1 (en) * 2013-03-15 2016-01-28 Genzyme Corporation Sequestrants of advanced glycation end product (age) precursors
WO2016064234A1 (ko) * 2014-10-22 2016-04-28 (주)아모레퍼시픽 라텍스 발포폼을 포함하는 화장료 조성물 담체
FR3038605B1 (fr) * 2015-07-06 2018-08-24 Universite Amiens Picardie Jules Verne Diamines primaires vicinales associees a des motifs chelateurs de metaux et/ou de radicaux libres, actives contre les stress carbonyle et oxydant et leur utilisation
JP6553491B2 (ja) * 2015-11-26 2019-07-31 オリエンタル酵母工業株式会社 最終糖化産物(AGEs)が関連する疾患の罹患又はそのリスクを予測する方法
CN112898342A (zh) * 2017-06-26 2021-06-04 上海日馨生物科技有限公司 苯磷硫胺衍生物、制备方法及其药物组合物
TWI685338B (zh) 2017-12-14 2020-02-21 柯瑞 伊里阿斯 J 使用非可吸收性口服投予之化合物之包括第2型糖尿病、脂肪肝炎及相關病況之人類代謝症候群之預防及治療
WO2020071258A1 (ja) * 2018-10-03 2020-04-09 味の素株式会社 タンパク質糖化抑制剤
CN112881581B (zh) * 2021-01-15 2022-04-01 中国海洋大学 一种定量检测水产品中吡咯素和甲基乙二醛氢咪唑酮的方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4908446A (en) * 1985-11-14 1990-03-13 The Rockefeller University Inhibitors of nonenzymatic cross-linking
US4758583A (en) * 1984-03-19 1988-07-19 The Rockefeller University Method and agents for inhibiting protein aging
US4900747A (en) * 1984-03-19 1990-02-13 The Rockefeller University Method and agents for removing advanced glycosylation endproducts
FI890918A (fi) * 1988-03-11 1989-09-12 Eisai Co Ltd Polypeptider.
US5232735A (en) 1990-06-01 1993-08-03 Bioresearch, Inc. Ingestibles containing substantially tasteless sweetness inhibitors as bitter taste reducers or substantially tasteless bitter inhibitors as sweet taste reducers
CA2104594C (en) * 1991-02-22 2004-05-11 Howard K. Shapiro Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology
JPH07500580A (ja) * 1991-09-09 1995-01-19 ペプテック リミテッド 糖尿病の合併症及び病因の処理方法
HUT68764A (en) * 1991-11-27 1995-07-28 Bioresearch Inc Eatable taste modifiers
GB9200415D0 (en) * 1992-01-09 1992-02-26 Bagshawe Kenneth D Inactivation of cytotoxic drugs
US5780588A (en) * 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5629174A (en) * 1993-07-26 1997-05-13 Cor Therapeutics, Inc. Recombinant C140 receptor
NZ334998A (en) * 1995-01-25 2000-11-24 Cor Therapeutics Inc Use of an agonist or antagonist for inhibiting the expression of a C140 receptor
DK61695A (da) * 1995-06-01 1996-12-02 Aarhus Oliefabrik As Kakaoflavouraktive peptider, DNA som koder for dem, fremgangsmåder til fremstilling af peptiderne og deres anvendelse til frembringelse af kakaoflavour
US6083758A (en) * 1997-04-09 2000-07-04 California Institute Of Technology Method for screening peptides for metal coordinating properties and fluorescent chemosensors derived therefrom
WO2000059875A2 (en) * 1999-04-05 2000-10-12 City Of Hope Novel inhibitors of formation of advanced glycation endproducts (age's)
US6605642B2 (en) * 1999-04-05 2003-08-12 City Of Hope Inhibitors of formation of advanced glycation endproducts (AGES)
US6787566B2 (en) * 1999-04-05 2004-09-07 City Of Hope Breakers of advanced glycation endproducts
US6589944B1 (en) 1999-04-05 2003-07-08 City Of Hope Breakers of advanced glycation endproducts
CA2371391A1 (en) * 1999-04-29 2000-11-09 City Of Hope Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (age's)
AU6842401A (en) * 2000-06-14 2001-12-24 Clontech Lab Inc Fluorescent timer proteins and methods for their use
DE10048260A1 (de) * 2000-09-29 2002-04-11 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Aminoguanidin und/oder dessen Derivaten und Strukturanaloga zur Hautaufhellung von Altersflecken und/oder zur Verhinderung der Hautbräunung, insbesondere der durch UV-Strahlung hervorgerufenen Hautbräunung
DE60233231D1 (de) * 2001-05-15 2009-09-17 Ortho Mcneil Janssen Pharm Ex-vivo-priming zur erzeugung cd40-ligand spezifischer zytotoxischer t-lymphozyten zur behandlung von autoimmun- und allergischen erkrankungen
EP1412324A4 (de) * 2001-06-11 2004-09-29 Xenoport Inc Aminosäurekonjugate, die anhaltende systemische konzentrationen von gaba-analoga ergeben
US20030135023A1 (en) * 2001-06-27 2003-07-17 Hans-Ulrich Demuth Peptide structures useful for competitive modulation of dipeptidyl peptidase IV catalysis
MXPA04003527A (es) * 2001-10-15 2005-06-20 Barnes Jewish Hospital Compuestos de antiresorcion osea.
ATE510852T1 (de) * 2001-10-30 2011-06-15 Dsm Ip Assets Bv Dermopharmazeutisch und kosmetisch wirksame oligopeptide
GB2403222A (en) * 2002-04-01 2004-12-29 Utah Ventures Ii L P Tissue-specific endothelial membrane proteins
JP2005537245A (ja) * 2002-06-26 2005-12-08 エントレメッド インコーポレイテッド タンパク質活性化レセプターのアンタゴニストを含む組成物および方法

Also Published As

Publication number Publication date
FR2883873A1 (fr) 2006-10-06
MA29416B1 (fr) 2008-04-01
CA2603386C (fr) 2018-03-06
MX2007012238A (es) 2008-03-18
EA200702104A1 (ru) 2008-02-28
CN101268093A (zh) 2008-09-17
EP1863832A1 (de) 2007-12-12
US9512176B2 (en) 2016-12-06
ZA200708835B (en) 2009-09-30
US20120252866A1 (en) 2012-10-04
KR101343929B1 (ko) 2013-12-24
KR20130110222A (ko) 2013-10-08
JP4695186B2 (ja) 2011-06-08
KR20080006557A (ko) 2008-01-16
WO2006103274A9 (fr) 2007-01-18
CN101268093B (zh) 2013-04-03
EP1863832B1 (de) 2012-01-04
US20080249030A1 (en) 2008-10-09
CA2603386A1 (fr) 2006-10-05
FR2883873B1 (fr) 2009-07-10
KR101536839B1 (ko) 2015-07-14
WO2006103274A8 (fr) 2007-05-03
JP2008534557A (ja) 2008-08-28
WO2006103274A1 (fr) 2006-10-05
BRPI0609783A2 (pt) 2011-10-11
AU2006228163A1 (en) 2006-10-05
BRPI0609783A8 (pt) 2018-03-13
GEP20104882B (en) 2010-01-11

Similar Documents

Publication Publication Date Title
ATE540051T1 (de) Age-inhibitoren
CY1115336T1 (el) Συνθεση της βορτεζομιμπης
NO20055922L (no) Farmasoytiske anvendbare salter av karboksylsyrderivater
WO2009005152A1 (ja) 新規脂質トリペプチド性ヒドロゲル化剤及びヒドロゲル
CY1111671T1 (el) Ετεροκυκλικη ενωση
TW200716518A (en) Acetylene derivatives
CY1114836T1 (el) Παραγωγο δικυκλικου γ-αμινοξεος
CY1112011T1 (el) Παραγωγα αζαδικυκλο (3.1.0) εξανιου χρησιμα ως ρυθμιστες υποδοχεων d3 ντοπαμινης
DK2078026T3 (da) Prodrug-salte af 2, 4-pyrimidinediamine-forbindelser og anvendelser deraf
CY1114932T1 (el) Αντιπαρασιτικοι παραγοντες
DOP2002000392A (es) Sales tartrato de 5,8,14 triazatetraciclo [10.3.1.024 0.4.9] hexadeca-2 (11), 3,5,7,9-pentaeno y composiciones farmaceuticas de las mismas
EA200701810A1 (ru) Производное изоксазолина и новый способ его получения
RU2014148530A (ru) Производные дипептида лизин-глутаминовая кислота
RS53003B (en) C7-FLUORO SUBSTITUTED TETRACYCLINE UNITS
CY1118173T1 (el) 5-[(3,3,3-τριφθορο-2-υδροξυ-1-αρυλπροπυλ)αμινο]-1h-κινολιν-2-ονες, μια διεργασια για την παραγωγη τους και η χρηση τους ως αντι-φλεγμονωδων παραγοντων
CY1116168T1 (el) Συγκρυσταλλοι και αλατα αναστολεων toy ccr3
RS52108B (en) 3-SUBSTITUTED [1,2,3] -BENZOTRIAZINONE UNIT TO INCREASE GLUTAMATERGIC SYNAPTIC ANSWERS
MY148953A (en) Substituted biphenyl carboxylic acids and derivatives thereof
EA200970372A1 (ru) Ингибитор развития болезни альцгеймера, содержащий гетероциклическое соединение
BRPI0409105A (pt) análogos de quinobenzoxazina substituìdos
BRPI0410861A (pt) métodos e composições para a produção de aminoácidos
DE602005020185D1 (de) Verfahren zur herstellung von 17-hydroxy-6 beta, 7 beta, 15 beta,16 beta-bismethylen-17alpha-pregn-4henprodukte für dieses verfahren
HUP0201083A2 (hu) Új atorvastatinsók és az azokat tartalmazó gyógyszerkészítmények
EA200600760A1 (ru) Новые соединения фенилпиридилпиперазина, способ их получения и фармацевтические композиции, содержащие их
CY1112279T1 (el) Εποξειδικη ενωση και μεθοδος για την παρασκευη της